Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)

Autor: Annette F. Okai, Lilyana Amezcua, Regina R. Berkovich, Angel R. Chinea, Keith R. Edwards, Brian Steingo, Aljoeson Walker, Alan K. Jacobs, Nadia Daizadeh, Mitzi J. Williams, the CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators

Publikováno v: Neurology and Therapy, Vol 8, Iss 2, Pp 367-381 (2019)

Abstract Introduction Multiple sclerosis (MS) patients of African descent have increased risk for disease progression and may be less responsive to disease-modifying therapy. Methods Patients in the CARE-MS studies received alemtuzumab 12 mg/day [ini

Externí odkaz: https://doaj.org/article/3c88f76d51334febbab539a6097228c0

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

Autor: Topaz investigators, Christopher LaGanke, Samuel F. Hunter, Zia Choudhry, Tjalf Ziemssen, Giancarlo Comi, Bart Van Wijmeersch, Daniel Pelletier, Ann D Bass, Sven Schippling, Care-Ms I, Care-Ms Ii, Camms, Lívia Sousa, Anthony Traboulsee, Regina Berkovich, Volker Limmroth, Carlo Pozzilli, Barry A Singer, Bernard M. J. Uitdehaag, Sara Eichau, Jeremy Hobart, Nadia Daizadeh

Publikováno v: CNS Drugs
Ziemssen, T, Bass, A D, Berkovich, R, Comi, G, Eichau, S, Hobart, J, Hunter, S F, LaGanke, C, Limmroth, V, Pelletier, D, Pozzilli, C, Schippling, S, Sousa, L, Traboulsee, A, Uitdehaag, B M J, Van Wijmeersch, B, Choudhry, Z, Daizadeh, N, Singer, B A & CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators 2020, ' Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease : Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study ', CNS Drugs, vol. 34, no. 9, pp. 973-988 . https://doi.org/10.1007/s40263-020-00749-x
CNS Drugs, 34(9), 973-988. Adis International Ltd

Background Alemtuzumab efficacy versus subcutaneous interferon-beta-1a (SC IFNB-1a) was demonstrated over 2 years in patients with relapsing-remitting multiple sclerosis, with continued efficacy over 7 additional years. Alemtuzumab is included as a r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a884d772f173242e654daa2c546c1549
https://pubmed.ncbi.nlm.nih.gov/32710396

Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years

Autor: Topaz investigators, Colin Mitchell, Elisabeth Gulowsen Celius, Stephen G Vincent, Renata Simm, Luke Chung, George J. Hutton, Anat Achiron, Camms , Care-Ms I, Care-Ms Ii, Camms, Jean-Raphael Schneider, David Rog, Marie Moore, Christina D. Chambers, Joy Derwenskus, Nadia Daizadeh, Pamela A. McCombe, Kerstin Hellwig, Virginia Devonshire, Lívia Sousa, Jiwon Oh, D Alastair S Compston

Background Relapsing-remitting multiple sclerosis (RRMS) is frequently diagnosed in women of reproductive age. Because the use of disease-modifying therapies (DMTs) early in the disease course is increasing, it is important to evaluate the safety of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::116fc430be851f4ebfdc13da3932c7a6
http://hdl.handle.net/10852/85205

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.